We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Expands Australian Women's Health Platform With Hers
Read MoreHide Full Article
Key Takeaways
Hims & Hers launches Hers in Australia, rebranding Juniper and expanding its women's healthcare services.
Hers offers personalized care, 24/7 support and broader specialties, backed by Eucalyptus' local presence.
HIMS leverages Eucalyptus' local presence to boost brand recognition, customer retention and revenues.
Hims & Hers Health (HIMS - Free Report) recently announced the launch of Hers, its women's health platform, in Australia. The launch rebrands Juniper, the women's health platform of Eucalyptus and introduces treatment programs covering hair regrowth, menopause and perimenopause and weight management. The platform combines clinically proven treatment options with medication, nutrition and fitness support, and access to a Care Team around the clock.
The move completes Hims & Hers' broader platform rollout in the country following Pilot's transition to Hims in August 2026 and the company's acquisition of Eucalyptus earlier this year.
Rebecca Holdt, VP of Product, International, said the platform aims to make quality women's healthcare more accessible through digital services, regardless of patients' locations. Matt Vickers, chief medical officer of Hims & Hers Australia, emphasized the importance of evidence-based care that considers women's overall health rather than treating individual symptoms in isolation.
HIMS Stock Trend Following the News
HIMS stock has lost 3% since the announcement on Monday. Year to date, the stock has declined 8.5% against the industry’s 19.4% growth and the S&P 500’s 13.8% rise.
The launch broadens HIMS' international growth strategy by extending its established women's healthcare model into Australia. Integrating Juniper into the Hers brand could help the company build stronger brand recognition, cross-specialty engagement and customer retention in the market. Supported by Eucalyptus' established local presence, the launch could strengthen HIMS’ recurring revenue opportunities as adoption of personalized digital healthcare grows in Australia.
HIMS currently has a market capitalization of $7.15 billion.
Image Source: Zacks Investment Research
More on the News
The launch addresses barriers to healthcare access in Australia, including affordability, perceived judgment and limited specialist availability in regional and rural areas. According to the company's May 2026 Juniper survey, 50% of Australians avoid accessing care primarily because of cost. Among 52% of women who reported feeling judged about their weight by a healthcare professional, 72% avoided seeking clinical help.
Hers will offer Australian women access to hair regrowth treatments and hormonal health services covering conditions such as polyendocrine metabolic ovarian syndrome (PMOS), menopause and perimenopause care and personalized weight management. The company's weight management offering includes a digital companion designed around women's needs, supported by its research and more than 20 peer-reviewed studies focused specifically on women. Women can request female practitioners and connect with a community of more than 27,000 women.
Existing Juniper patients will continue receiving care from their current Australian practitioners and care team, now with access to a broader range of specialties. Gus Wood will oversee the Australian market as General Manager, while Dr. Matt Vickers will serve as chief medical officer of Hims & Hers Australia.
Industry Prospects Favoring the Market
According to IMARC Group, Australia telehealth market was valued at $542.3 million in 2025 and is projected to witness a CAGR of 18.2% from 2026 to 2034.
Factors like expanding digital health infrastructure, rising chronic diseases, growing mental health service demand, AI integration in virtual care platforms, medicare reimbursement frameworks and improving broadband access in regional areas are supporting market growth.
Other News
In August, Hims & Hers has expanded into Australia, marking its first entry into the Asia-Pacific market following its acquisition of Eucalyptus. The company rebranded Eucalyptus’ men’s health platform, Pilot, as Hims, offering personalized care for sexual health, weight management and hair loss. The expansion supports Hims & Hers’ goal of generating $1 billion in international annual revenues within three years.
Currently, Hims & Hers carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Expands Australian Women's Health Platform With Hers
Key Takeaways
Hims & Hers Health (HIMS - Free Report) recently announced the launch of Hers, its women's health platform, in Australia. The launch rebrands Juniper, the women's health platform of Eucalyptus and introduces treatment programs covering hair regrowth, menopause and perimenopause and weight management. The platform combines clinically proven treatment options with medication, nutrition and fitness support, and access to a Care Team around the clock.
The move completes Hims & Hers' broader platform rollout in the country following Pilot's transition to Hims in August 2026 and the company's acquisition of Eucalyptus earlier this year.
Rebecca Holdt, VP of Product, International, said the platform aims to make quality women's healthcare more accessible through digital services, regardless of patients' locations. Matt Vickers, chief medical officer of Hims & Hers Australia, emphasized the importance of evidence-based care that considers women's overall health rather than treating individual symptoms in isolation.
HIMS Stock Trend Following the News
HIMS stock has lost 3% since the announcement on Monday. Year to date, the stock has declined 8.5% against the industry’s 19.4% growth and the S&P 500’s 13.8% rise.
The launch broadens HIMS' international growth strategy by extending its established women's healthcare model into Australia. Integrating Juniper into the Hers brand could help the company build stronger brand recognition, cross-specialty engagement and customer retention in the market. Supported by Eucalyptus' established local presence, the launch could strengthen HIMS’ recurring revenue opportunities as adoption of personalized digital healthcare grows in Australia.
HIMS currently has a market capitalization of $7.15 billion.
Image Source: Zacks Investment Research
More on the News
The launch addresses barriers to healthcare access in Australia, including affordability, perceived judgment and limited specialist availability in regional and rural areas. According to the company's May 2026 Juniper survey, 50% of Australians avoid accessing care primarily because of cost. Among 52% of women who reported feeling judged about their weight by a healthcare professional, 72% avoided seeking clinical help.
Hers will offer Australian women access to hair regrowth treatments and hormonal health services covering conditions such as polyendocrine metabolic ovarian syndrome (PMOS), menopause and perimenopause care and personalized weight management. The company's weight management offering includes a digital companion designed around women's needs, supported by its research and more than 20 peer-reviewed studies focused specifically on women. Women can request female practitioners and connect with a community of more than 27,000 women.
Existing Juniper patients will continue receiving care from their current Australian practitioners and care team, now with access to a broader range of specialties. Gus Wood will oversee the Australian market as General Manager, while Dr. Matt Vickers will serve as chief medical officer of Hims & Hers Australia.
Industry Prospects Favoring the Market
According to IMARC Group, Australia telehealth market was valued at $542.3 million in 2025 and is projected to witness a CAGR of 18.2% from 2026 to 2034.
Factors like expanding digital health infrastructure, rising chronic diseases, growing mental health service demand, AI integration in virtual care platforms, medicare reimbursement frameworks and improving broadband access in regional areas are supporting market growth.
Other News
In August, Hims & Hers has expanded into Australia, marking its first entry into the Asia-Pacific market following its acquisition of Eucalyptus. The company rebranded Eucalyptus’ men’s health platform, Pilot, as Hims, offering personalized care for sexual health, weight management and hair loss. The expansion supports Hims & Hers’ goal of generating $1 billion in international annual revenues within three years.
Hims & Hers Health, Inc. Price
Hims & Hers Health, Inc. price | Hims & Hers Health, Inc. Quote
HIMS’ Zacks Rank & Key Picks
Currently, Hims & Hers carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.